Ranbaxy gets tentative US nod for BP drug
Pharma major Ranbaxy Laboratorieds Ltd (RLL) has received tentative clearance to market the bio-equivalent of Lotensin, the hypertension drug from Novartis Pharmaceuticals.
Pharma major Ranbaxy Laboratorieds Ltd (RLL) has received tentative clearance to market the bio-equivalent of Lotensin, the hypertension drug from Novartis Pharmaceuticals.